COMMUNIQUÉS West-GlobeNewswire
-
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
14/01/2026 -
Altanine Shares Industry Perspective on the Future of Generics and the Role of Value-Added Formulations
14/01/2026 -
ApolloMD Announces Leadership Appointments to Strengthen Hospital Operations and Revenue Performance
14/01/2026 -
Patterson Dental and Dentsply Sirona Renew U.S. Dental Technology Distribution Partnership
14/01/2026 -
Statement from Unity Consortium on Announced Changes to the U.S. Childhood and Adolescent Immunization Schedule
14/01/2026 -
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness
14/01/2026 -
Glucose Health, Inc. Reports Debt-Free Balance Sheet and Previews New Soluble Fiber Brand
14/01/2026 -
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
14/01/2026 -
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
14/01/2026 -
RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study
14/01/2026 -
Verano Strengthens National Product Portfolio in Industry’s Fastest-Growing Category with Launch of Swift Lifts as Standalone Pre-roll Brand
14/01/2026 -
Human Appeal Concludes First-Ever U.S. Winter Coat Drive
14/01/2026 -
Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future
14/01/2026 -
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
14/01/2026 -
De nouvelles données renforcent l’engagement d’Ipsen à proposer des solutions et à combler les lacunes de prise en charge dans les maladies neurologiques lors du congrès TOXINS
14/01/2026 -
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
14/01/2026 -
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
14/01/2026 -
Aqua free enters the B2C market with “Shower2go”: a portable travel shower for safer showering on the go – helping to reduce exposure to Legionella
13/01/2026 -
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
13/01/2026
Pages